Seglentis Patent Expiration

Seglentis is a drug owned by Kowa Pharmaceuticals America Inc. It is protected by 7 US drug patents filed from 2021 to 2022 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Jun 03, 2031. Details of Seglentis's patents and their expiration are given in the table below.


Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8598152 Co-crystals of tramadol and coxibs
Apr, 2030

(5 years from now)

Active
US9012440 Co-crystals of tramadol and coxibs
Apr, 2030

(5 years from now)

Active
US10245276 Co-crystals of tramadol and coxibs
Apr, 2030

(5 years from now)

Active
US10238668 Co-crystals of tramadol and coxibis
Apr, 2030

(5 years from now)

Active
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11478488 Co-crystals of tramadol and coxibs
Apr, 2030

(5 years from now)

Active
US10548909 Co-crystals of tramadol and coxibs
Apr, 2030

(5 years from now)

Active
US8846744 Pharmaceutical compositions of co-crystals of tramadol and coxibs
Jun, 2031

(6 years from now)

Active


FDA has granted several exclusivities to Seglentis. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Seglentis, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Seglentis.

Exclusivity Information

Seglentis holds 1 exclusivities out of which none have expired. Its last outstanding exclusivity is set to expire in 2024. Details of Seglentis's exclusivity codes and their expiration dates are given below.


Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Oct 15, 2024

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Seglentis is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Seglentis's family patents as well as insights into ongoing legal events on those patents.

Seglentis's family patents

Seglentis has patent protection in a total of 35 countries. It's US patent count contributes only to 13.1% of its total global patent coverage. 4 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree for Seglentis.

Family Patents

Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳



Generic Launch

Generic Release Date:

Seglentis's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Jun 03, 2031 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Seglentis Generics:

There are no approved generic versions for Seglentis as of now.





About Seglentis

Seglentis is a drug owned by Kowa Pharmaceuticals America Inc. It is used for managing pain in adults. Seglentis uses Celecoxib; Tramadol Hydrochloride as an active ingredient. Seglentis was launched by Kowa Pharms in 2021.

Market Authorisation Date:

Seglentis was approved by FDA for market use on 15 October, 2021.

Active Ingredient:

Seglentis uses Celecoxib; Tramadol Hydrochloride as the active ingredient. Check out other Drugs and Companies using Celecoxib; Tramadol Hydrochloride ingredient

Treatment:

Seglentis is used for managing pain in adults.

Dosage:

Seglentis is available in tablet form for oral use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
56MG;44MG TABLET Prescription ORAL